Results 131 to 140 of about 25,584,253 (297)

UMOD Genotype and Clinical Outcomes in Heart Failure Patients Treated with Loop Diuretics: A UK Biobank Pharmacogenetic Cohort Study

Clinical Pharmacology &Therapeutics, EarlyView.
Uromodulin (UMOD) regulates tubular sodium handling and modulates NKCC2, the molecular target of loop diuretics (LD). Although UMOD variants have been associated with blood pressure and hypertension, their pharmacogenetic relevance in heart failure (HF) remains unknown.
Reinhold Kreutz, Pimrapat Gebert, Jingwen Luo, Paraskevi Tassopoulou, Juliane Bolbrinker, Antonios Douros   +5 more
wiley   +1 more source

Urinary Angiotensin Converting Enzyme 2 Increases in Patients With Type 2 Diabetic Mellitus

Kidney & Blood Pressure Research, 2015
Background/Aims: Angiotensin converting enzyme 2 (ACE2) is highly expressed in the kidney and recognized to be renoprotective by degrading Angiotensin II to Angiotensin (1-7) in diabetic nephropathy.
Yaoxian Liang, Hui Deng, Shuhong Bi, Zhuan Cui, Lata A, Danxia Zheng, Yue Wang   +6 more
doaj   +1 more source

Initiation of Gabapentin with Opioids and Risk of Respiratory Cardiovascular and Opioid‐Related Adverse Events Following Surgery for Breast Cancer

Clinical Pharmacology &Therapeutics, EarlyView.
Pain is a key determinant of quality‐of‐life following breast cancer surgery, the most common cancer operation in the United States. Gabapentinoids are frequently prescribed for pain management, yet their respiratory, cardiovascular, and opioid‐related adverse effects remain unclear.
Jyun‐Heng Lai, Anton L V Avanceña, Juan P Cata, Jamie C. Barner, Sharon H. Giordano, Chanhyun Park, Hui Zhao, Kirk E. Evoy, John K. Lin, Jennifer C. Spencer, Mariana Chavez‐MacGregor, Kelly K. Hunt, Kerollos Nashat Wanis   +12 more
wiley   +1 more source

Characterisation of the structural motifs Involved in the cleavage and secretion of human angiotensin-converting enzyme [PDF]

, 2014
Includes bibliographical references.Angiotensin converting enzyme is an ectoprotein prone to regulated proteolytic solubilisation by an as yet unknown protease or sheddase.
Conrad, Nailah
core   +1 more source

Enhancing Evidence Generation by Linking Randomized Clinical Trials to Real‐World Data: The INVESTED‐Medicare Linkage Study

Clinical Pharmacology &Therapeutics, EarlyView.
Real‐world evidence (RWE) derived from real‐world data (RWD) can complement randomized controlled trials (RCTs), yet the validity of RWD relative to RCT data remains insufficiently characterized. We obtained post hoc consent and linked individual participant data from the US‐based INVESTED trial (2016–2019) with Medicare fee‐for‐service claims (2012 ...
Hanseul Cho, HoJin Shin, Mehdi Najafzadeh, Brian Claggett, Janinne Ortega‐Montiel, Jun Liu, Julie M. Paik, Narlina F. Lalani, Marie C. Bradley, John Concato, Scott D. Solomon, Orly Vardeny, Elisabetta Patorno   +12 more
wiley   +1 more source

The Potential of the Use of the Flavonoid Fisetin in the Treatment of Coronavirus by Inhibition of Angiotensin Converting Enzyme 2

Majallah-i dānishgāh-i ̒ulūm-i pizishkī-i Arāk, 2021
In December 2019, a new type of coronavirus called COVID-19 was identified as an unknown cause of pneumonia in Wuhan, China. The pandemic virus was transmitted to humans from a type of seafood that could spread significantly among humans in a short time.
Seyedeh Sara Azadeh, Hoda Keshmiri Neghab   +1 more
doaj  

Urogenital Infection Risk Associated With SGLT2 Inhibitors Versus DPP‐4 Inhibitors in Type 2 Diabetes and Chronic Kidney Disease: A Nationwide Target Trial Emulation

Clinical Pharmacology &Therapeutics, EarlyView.
Although sodium‐glucose cotransporter‐2 inhibitors (SGLT2i) are recommended for patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD), concerns regarding urogenital infections persist. Therefore, we evaluated the risk of urinary tract infection (UTI) and genital tract infection (GTI) after SGLT2i initiation in this population ...
Young‐Mi Ah, Junsung Nam, Jung Wook Youn, Yun Mi Yu, Soyoung Kang   +4 more
wiley   +1 more source

Socio‐economic inequalities and heart failure morbidity and mortality: A systematic review and data synthesis

ESC Heart Failure, Volume 12, Issue 2, Page 927-941, April 2025.
Abstract Socio‐economic status (SES) has been associated with incident and prevalent heart failure (HF), as well as its morbidity and mortality. However, the precise nature of the relationship between SES and HF remains unclear due to inconsistent data. This study aims to provide a comprehensive assessment and data synthesis of the relationship between
Abdul Shakoor, Willemijn A. van Maarschalkerwaart, Jeroen Schaap, Rudolf A. de Boer, Nicolas M. van Mieghem, Eric H. Boersma, Loek van Heerebeek, Jasper J. Brugts, Robert M.A. van der Boon   +8 more
wiley   +1 more source

Incident heart failure: comparing management and outcome in primary and hospital settings in Western Sweden 2008–2017

ESC Heart Failure, Volume 12, Issue 2, Page 832-838, April 2025.
Abstract Aim Heart failure (HF) is a highly prevalent condition managed in both primary care (PC) and hospital care (HC)‐based settings. HF patients managed in these two settings may differ in their demography, comorbidities and outcomes, so we aimed to compare the patient management in PC and HC in the Västra Götaland Region (VGR) in Sweden.
Xiaojing Chen, Aldina Pivodic, Maria Schaufelberger, Annika Rosengren, Michael Fu   +4 more
wiley   +1 more source

Expression of angiotensin converting enzyme 2 in patients with oral squamous cell carcinoma

Oral Oncology Reports
Background: Oral squamous cell carcinoma (OSCC), being a multifactorial cancer, is significantly higher in South Asian countries and only 70 % of the cases are reported only in its advanced stages.
Shivani Sivasakthivel, Pratibha Ramani, Selvaraj Jayaraman   +2 more
doaj   +1 more source